# A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer

> **NCT06791161** · — · ENROLLING_BY_INVITATION · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 300 (estimated)

## Conditions studied

- Breast

## Interventions

- **DRUG:** Endocrine drug +CDK4/6 inhibitor or PRAP inhibitor or Endocrine drug +CDK4/6 inhibitor+PARP inhibitor

## Key facts

- **NCT ID:** NCT06791161
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-01-19
- **Primary completion:** 2030-01-18
- **Final completion:** 2035-01-18
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06791161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06791161, "A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06791161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*